Sorry RP yes that's one application cohort only brutally one revenue stream potential of 1.5 billion usd - 2.2 billion odd Aud per annum... ie 10 years 22 billion AUD
And of course we have multiple concurrent trials we may find Paxalisib will benefit other patients - in fact its been shown so much support by clinicians I think it's almost inevitable we'll get more use cases - this is all very exciting for patients and feeds the
"the ever-growing enthusiasm of clinicians"
a statement like like that is not one made if clinicians are moving on to other focuses.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia Half Year Accounts and Chairman's letter
Ann: Kazia Half Year Accounts and Chairman's letter, page-87
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)